Charles River Laboratories International, Inc.
CRL
$166.91
-$2.73-1.61%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.29M | 16.57M | 418.15M | 435.88M | 438.82M |
| Total Depreciation and Amortization | 351.85M | 352.34M | 340.15M | 330.82M | 322.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 430.78M | 395.99M | -12.60M | 1.84M | 1.70M |
| Change in Net Operating Assets | 19.05M | -30.33M | 50.46M | -18.73M | -58.53M |
| Cash from Operations | 776.39M | 734.58M | 796.16M | 749.82M | 704.40M |
| Capital Expenditure | -213.15M | -232.97M | -235.67M | -262.90M | -290.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -5.48M | -5.48M | -150.10M | -150.10M | -144.62M |
| Divestitures | 17.44M | -- | -- | -- | -- |
| Other Investing Activities | -3.59M | -6.64M | -21.58M | -52.59M | -44.91M |
| Cash from Investing | -204.77M | -245.09M | -407.35M | -465.59M | -480.33M |
| Total Debt Issued | 1.20B | 1.08B | 1.42B | 1.24B | 884.74M |
| Total Debt Repaid | -1.35B | -1.49B | -1.64B | -1.52B | -986.83M |
| Issuance of Common Stock | 2.37M | 23.88M | 29.05M | 32.21M | 35.31M |
| Repurchase of Common Stock | -462.96M | -119.18M | -119.19M | -18.44M | -14.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -60.37M | -43.44M | -43.68M | -34.36M | -11.14M |
| Cash from Financing | -674.60M | -550.93M | -351.48M | -306.81M | -92.42M |
| Foreign Exchange rate Adjustments | -3.82M | -17.47M | 8.70M | -5.19M | -2.01M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.81M | -78.91M | 46.02M | -27.77M | 129.64M |